Reports survival outcomes in stage IIIb AL amyloidosis, suggesting potential benefits from daratumumab treatment.
of baseline characteristics, treatment regimens, hematologic and cardiac responses, and survival outcomes among 51 patients with Mayo stage IIIb AL amyloidosis treated with daratumumab-based frontline therapy.
No takes yet. Share an insight, caveat, or question.
Zhen et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: